Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big Pharma companies keen on its promising pipeline in cardiovascular and neuromuscular diseases. Sources indicate that Novartis (NYSE: NVS) was initially leading the charge against competitors AstraZeneca (AZ, NASDAQ: AZN) and Johnson & Johnson (J&J, NYSE: JNJ) before withdrawing from the race last week.
Amgen (NASDAQ: AMGN) is now said to be evaluating Cytokinetics’s proposal, which values the company between USD 130 and 145 per share. This interest is primarily driven by Cytokinetics’s lead candidate, aficamten, a small-molecule inhibitor currently advancing through Phase III trials as a treatment for hypertrophic cardiomyopathy (HCM).- Flcube.com
